Bromocriptine

DRUG INFORMATION

  ADULT
    - Take bromocriptine mesylate capsules orally with food ( 2.2 ) Recommended dosage
      for hyperprolactinemia-associated dysfunction is 1.25 mg (one-half of a tablet) to
      2.5 mg once daily.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage
      and administration', retrieved 2026-08-29
    - Increase the dosage up to 2.5 mg once daily every two to seven days within a
      recommended dosage of 2.5 mg to 15 mg once daily ( 2.3 ) Recommended dosage for
      prolactin-secreting adenomas is 1.25 mg to 2.5 mg once daily.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage
      and administration', retrieved 2026-08-29
    - Increase the dosage within a recommended dosage of 2.5 mg to 10 mg once daily (
      2.4 ) Recommended dosage for acromegaly is 1.25 mg to 2.5 mg once at bedtime for 3
      days.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage
      and administration', retrieved 2026-08-29

  CHILD
    - Before initiating bromocriptine mesylate capsules, evaluate for valvular heart
      disease, including with an echocardiogram. If valvular disease is detected, do not
      administer bromocriptine mesylate ( 2.1 ). Take bromocriptine mesylate capsules
      orally with food ( 2.2 ) Recommended dosage for hyperprolactinemia-associated
      dysfunction is 1.25 mg (one-half of a tablet) to 2.5 mg once daily.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage
      and administration', retrieved 2026-08-29
    - Increase the bromocriptine mesylate dosage up to 2.5 mg once daily every two to
      seven days as tolerated until an optimal therapeutic response is achieved within a
      recommended dosage of 2.5 mg to 15 mg once daily.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'dosage
      and administration', retrieved 2026-08-29

  RENAL IMPAIRMENT
    - ( 5.1 ) Pleural, Pulmonary and Retroperitoneal Fibrosis: During bromocriptine
      mesylate treatment monitor for signs and symptoms of progressive fibrosis, (e.g.,
      pleuro-pulmonary disease, renal impairment, ureteral/abdominal vascular
      obstruction).
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'warnings
      and cautions', retrieved 2026-08-29
    - Renal impairment or ureteral/abdominal vascular obstruction (e.g., pain in the
      loin/flank, lower limb edema, abdominal masses or tenderness that may indicate
      retroperitoneal fibrosis).
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'warnings
      and cautions', retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for bromocriptine (Bromocriptine
      mesylate), retrieved 2026-08-29

  PREGNANCY
    - Risk Summary Pregnancy in Patients with Hyperprolactinemia-Associated Dysfunction
      and Prolactin-Secreting Adenomas: In patients being treated with bromocriptine
      mesylate capsules for hyperprolactinemia, bromocriptine mesylate should generally
      be withdrawn when pregnancy is diagnosed.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section
      'pregnancy', retrieved 2026-08-29
    - If bromocriptine mesylate is continued or reinstituted in select patients to
      manage a prolactin-secreting macroadenoma and a patient experiences a hypertensive
      disorder of pregnancy, the benefit of continuing bromocriptine mesylate capsules
      should be weighed against the possible risk of its use during a hypertensive
      disorder of pregnancy.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section
      'pregnancy', retrieved 2026-08-29
    - Pregnancy in Patients with Acromegaly : In patients being treated with
      bromocriptine mesylate for acromegaly who subsequently become pregnant, a decision
      should be made as to whether bromocriptine mesylate continues to be medically
      necessary or can be withdrawn.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section
      'pregnancy', retrieved 2026-08-29

  BREASTFEEDING
    - Pregnancy: See the Full Prescribing Information regarding the recommendations for
      using bromocriptine mesylate during pregnancy ( 8.1 ) Lactation: Avoid the use of
      bromocriptine mesylate during lactation in postpartum females.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'use in
      specific populations', retrieved 2026-08-29
    - Postpartum Period: Avoid use of bromocriptine mesylate capsules for the inhibition
      or suppression of postpartum physiologic lactation because of the risk of serious
      adverse reactions [see Warnings and Precautions ( 5.4 )] .
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'use in
      specific populations', retrieved 2026-08-29
    - No teratological or embryotoxic effects of bromocriptine were produced in any of
      six offspring from six monkeys at a bromocriptine dose level of 2 mg/kg. 8.2
      Lactation Risk Summary Avoid the use of bromocriptine mesylate capsules during
      lactation in postpartum females.
      Source: US FDA label for bromocriptine (Bromocriptine mesylate), section 'use in
      specific populations', retrieved 2026-08-29